Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
- 4 years ago
Hippocratic Post
COVID-19 Update: Chloroquine / Hydroxychloroquine and Azithromycin
Related Post
- Global immunization has saved at least 154 million
Global immunization efforts have saved at least 154 million lives over the past 50 years: WHO,…
-
Relative deficiency in immune cells can account for poorer vaccination responses in the older population
In a study examining the ageing immune system and what makes it less efficient, researchers…
-
How Pathway Is Paving the Way for a Healthier Future
Revolutionizing Healthcare: How Pathway Is Paving the Way for a Healthier Future: Innovation and the…
Leave a Reply
You must be logged in to post a comment.